Sitryx Therapeutics has completed enrollment ahead of schedule in its Phase 1b trial of SYX-5219, a first-in-class oral PKM2 modulator, targeting moderate to severe atopic dermatitis. The randomized, placebo-controlled study involves 50 adults across the US and Europe and aims to evaluate safety, tolerability, and initial efficacy. This milestone highlights strong patient and clinician interest in a novel oral treatment that could offer durable disease remission by modulating immune function rather than just managing symptoms. Data from the trial is expected in the fourth quarter of 2026, following promising Phase 1a results showing safety and immune modulation.
GXO Logistics has launched a new distribution center in Ferentino, Italy, to support Action's expansion in Central and Southern Italy. The facility, GXO's second for Action in Italy, will grow its workforce from over 200 to 300 employees and features...
CureWise, led by founder Steve Brown, has launched an AI-powered precision oncology platform designed to help cancer patients understand their unique disease and explore personalized treatment options. The platform integrates medical records securely...
Brunswick Corporation's Navico Group announced operational changes at its Lowell, Michigan facility aimed at reducing fixed costs and improving efficiency. The update includes expanding insourcing, collaborating with outside partners, and better spac...
WeRide, Geely Farizon, and Kwoon Chung Bus Holdings have jointly developed right-hand-drive Robotaxis tailored for markets like Hong Kong, where such vehicles are currently unavailable. This collaboration leverages each company's strengths in autonom...
The Activated Alumina Market, valued at $1.22 billion in 2025, is projected to grow at a CAGR of 6.44% to reach $2.26 billion by 2035. Growth is fueled by rising demand for water treatment solutions, industrial gas drying, and environmental complianc...
